|
JPS6019790B2
(ja)
|
1977-11-18 |
1985-05-17 |
株式会社日立製作所 |
光硬化型接着性組成物とそれを用いて被着体を接着する方法
|
|
US4353887A
(en)
|
1979-08-16 |
1982-10-12 |
Ciba-Geigy Corporation |
Divisible tablet having controlled and delayed release of the active substance
|
|
JPS6019790A
(ja)
|
1983-07-14 |
1985-01-31 |
Yakult Honsha Co Ltd |
新規なカンプトテシン誘導体
|
|
AU2309692A
(en)
|
1991-07-03 |
1993-02-11 |
Cryolife, Inc. |
Method for stabilization of biomaterials
|
|
US5474796A
(en)
|
1991-09-04 |
1995-12-12 |
Protogene Laboratories, Inc. |
Method and apparatus for conducting an array of chemical reactions on a support surface
|
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
DE69333928T2
(de)
|
1992-04-30 |
2006-08-17 |
Probitas Pharma Inc., Los Angeles |
Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
JP3734262B2
(ja)
|
1993-03-25 |
2006-01-11 |
メルク エンド カンパニー インコーポレーテッド |
血管内皮細胞増殖因子阻害剤
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US6040157A
(en)
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
|
GB9410533D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
In situ hybridisation and immuno-Chemical localisation of a growth factor
|
|
TW438775B
(en)
|
1995-04-07 |
2001-06-07 |
Pharmacia & Upjohn Co Llc |
Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Ｖｅｇｆ結合性ポリペプチド
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US5763401A
(en)
|
1996-07-12 |
1998-06-09 |
Bayer Corporation |
Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
|
|
AU738806B2
(en)
|
1996-09-24 |
2001-09-27 |
Merck & Co., Inc. |
Gene therapy for inhibition of angiogenesis
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
DE19724793A1
(de)
|
1997-06-06 |
1998-12-10 |
Schering Ag |
D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften
|
|
US6075007A
(en)
|
1997-07-17 |
2000-06-13 |
Regeneron Pharmaceuticals, Inc. |
Modified noggin polypeptide and compositions
|
|
JPH1180024A
(ja)
|
1997-09-12 |
1999-03-23 |
Toagosei Co Ltd |
角膜血管新生阻害剤
|
|
US6436897B2
(en)
|
1998-06-01 |
2002-08-20 |
Celtrix Pharmaceuticals, Inc. |
Pharmaceutical formulations for IGF/IGFBP
|
|
DE19841985A1
(de)
|
1998-09-03 |
2000-03-09 |
Schering Ag |
Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
|
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
|
WO2000034337A1
(en)
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
|
AP1243A
(en)
|
1999-02-01 |
2004-02-02 |
Servier Lab |
Core tablet for controlled release of gliclazide after oral administration.
|
|
WO2000064946A2
(en)
|
1999-04-28 |
2000-11-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
|
WO2000066125A1
(en)
|
1999-04-29 |
2000-11-09 |
Aventis Pharma S.A. |
Method for treating cancer using camptothecin derivatives and 5-fluorouracil
|
|
US6833349B2
(en)
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
IL146890A0
(en)
|
1999-06-08 |
2002-08-14 |
Regeneron Pharma |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7001892B1
(en)
|
1999-06-11 |
2006-02-21 |
Purdue Research Foundation |
Pharmaceutical materials and methods for their preparation and use
|
|
DE19938724A1
(de)
|
1999-08-16 |
2001-02-22 |
Tetra Laval Holdings & Finance |
Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen
|
|
GB0008269D0
(en)
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
|
US6500633B1
(en)
|
2000-04-26 |
2002-12-31 |
Atairgin Technologies, Inc. |
Method of detecting carcinomas
|
|
AR028424A1
(es)
|
2000-05-10 |
2003-05-07 |
Bayer Corp |
Metodo para regular la angiogenesis utilizando proteina ryk
|
|
ATE442862T2
(de)
|
2000-10-12 |
2009-10-15 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
|
US20030092019A1
(en)
|
2001-01-09 |
2003-05-15 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
|
|
US20040023864A1
(en)
|
2001-05-09 |
2004-02-05 |
Steve Roczniak |
Method of regulating angiogenesis using ryk protein
|
|
DE60235013D1
(de)
|
2001-07-25 |
2010-02-25 |
Facet Biotech Corp |
Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
|
|
CN1276923C
(zh)
|
2002-03-01 |
2006-09-27 |
法玛西雅意大利公司 |
盐酸伊立替康的结晶多晶型物
|
|
JP2004006671A
(ja)
|
2002-03-22 |
2004-01-08 |
Sanyo Electric Co Ltd |
電荷結合素子およびその製造方法
|
|
ES2278333T3
(es)
|
2003-03-28 |
2007-08-01 |
Regeneron Pharmaceuticals, Inc. |
Antagonistas de vegf para el tratamiento de la diabetes.
|
|
BRPI0403964B8
(pt)
|
2003-04-04 |
2021-05-25 |
Genentech Inc |
formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
|
|
AU2004242586C1
(en)
|
2003-05-28 |
2011-02-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using VEGF antagonists
|
|
US7300654B2
(en)
|
2003-05-28 |
2007-11-27 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection in high risk keratoplasty patients
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
CA2519875C
(en)
|
2003-06-06 |
2014-01-14 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with vegf inhibitors
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
JP2007501239A
(ja)
|
2003-08-06 |
2007-01-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用
|
|
US20050196340A1
(en)
|
2003-08-06 |
2005-09-08 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
|
AU2003257853A1
(en)
|
2003-08-14 |
2005-03-07 |
Fujitsu Limited |
Computer device and cluster server device
|
|
NZ592039A
(en)
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
EP1529620B1
(fr)
|
2003-11-06 |
2009-02-25 |
Nestlé Waters Management & Technology |
Procédé de fabrication de contenants en résine polyester
|
|
WO2005046602A2
(en)
|
2003-11-10 |
2005-05-26 |
Greenville Hospital System |
Vegf receptor antagonists
|
|
WO2005072772A1
(en)
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
|
CN101102786A
(zh)
|
2004-06-10 |
2008-01-09 |
瑞泽恩制药公司 |
施用并利用vegf抑制剂治疗人类癌症的方法
|
|
US20050281822A1
(en)
|
2004-06-18 |
2005-12-22 |
Cedarbaum Jesse M |
Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
|
|
US7378095B2
(en)
|
2004-07-30 |
2008-05-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating type I diabetes by blocking VEGF-mediated activity
|
|
PL1802334T3
(pl)
|
2004-10-21 |
2013-01-31 |
Genentech Inc |
Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
|
|
FR2878749B1
(fr)
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
WO2006088650A2
(en)
|
2005-02-02 |
2006-08-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
EP1853298A2
(en)
|
2005-02-11 |
2007-11-14 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
|
|
WO2006099154A1
(en)
|
2005-03-11 |
2006-09-21 |
Regeneron Pharmaceuticals, Inc. |
Treating anemia by inhibition of vegf
|
|
DK2586459T3
(en)
|
2005-03-25 |
2017-09-11 |
Regeneron Pharma |
VEGF antagonist formulations
|
|
CN101237880B
(zh)
|
2005-08-12 |
2011-09-21 |
瑞泽恩制药公司 |
通过vegf拮抗剂的皮下给药治疗疾病
|
|
US7354582B2
(en)
|
2006-03-10 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF antagonists for the treatment of malignant gliomas
|
|
RU2432155C3
(ru)
|
2006-06-16 |
2017-11-17 |
Ридженерон Фармасьютикалз, Инк. |
Составы антагониста vegf, подходящие для интравитреального введения
|
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
|
US20100216168A1
(en)
|
2007-03-23 |
2010-08-26 |
Precision Therapeutics, Inc. |
Methods for evaluating angiogenic potential in culture
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN100546578C
(zh)
*
|
2007-08-10 |
2009-10-07 |
河北医科大学 |
一种抗癌药物组合物及其在制备抗癌药物中的应用
|
|
ES2684340T3
(es)
|
2007-10-04 |
2018-10-02 |
Onyx Therapeutics, Inc. |
Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
|
|
NZ628598A
(en)
|
2007-11-30 |
2016-09-30 |
Genentech Inc |
Vegf polymorphisms and anti-angiogenesis therapy
|
|
EP2143542A1
(fr)
|
2008-07-07 |
2010-01-13 |
Nestec S.A. |
Procédé et dispositif de conditionnement d'un liquide alimentaire
|
|
FR2933702A1
(fr)
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
WO2010022201A2
(en)
|
2008-08-22 |
2010-02-25 |
Osteogenex Inc. |
Folinic acid derivatives for promoting bone growth
|
|
WO2010042903A1
(en)
|
2008-10-09 |
2010-04-15 |
Alfagene Bioscience, Inc |
Use and identification of biomarkers for gastrointestinal diseases
|
|
EP2540843B1
(en)
|
2008-11-05 |
2014-07-02 |
Genentech, Inc. |
Genetic polymorphisms in age-related macular degeneration
|
|
SG174963A1
(en)
|
2009-03-31 |
2011-11-28 |
Roche Glycart Ag |
Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
|
|
WO2010124264A2
(en)
|
2009-04-24 |
2010-10-28 |
University Of Southern California |
Genetic variants in angiogenesis pathway associated with clinical outcome
|
|
CA2768822C
(en)
|
2009-07-31 |
2017-10-17 |
Amcor Limited |
Hot-fill container
|
|
US8221753B2
(en)
*
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
AU2012228544B2
(en)
|
2011-02-23 |
2015-06-11 |
Sanofi |
Single nucleotide polymorphisms in the promoter of VEGFA gene and their use as predictive markers for anti-VEGF treatments
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
JP6019790B2
(ja)
|
2012-06-19 |
2016-11-02 |
富士電機株式会社 |
接合方法及び接合部材
|
|
AR091967A1
(es)
|
2012-08-02 |
2015-03-11 |
Sanofi Sa |
Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
|
|
WO2016008975A1
(en)
|
2014-07-18 |
2016-01-21 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
|
|
AU2017211247B2
(en)
|
2016-01-25 |
2023-03-09 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
|